Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma.

cell-free DNA copy number analysis mutational profile primary mediastinal large B-cell lymphoma

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
28 Jun 2022
Historique:
received: 15 05 2022
revised: 23 06 2022
accepted: 27 06 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

High-throughput sequencing of cell-free DNA (cfDNA) has emerged as a promising noninvasive approach in lymphomas, being particularly useful when a biopsy specimen is not available for molecular analysis, as it frequently occurs in primary mediastinal large B-cell lymphoma (PMBL). We used cfDNA for genomic characterization in 20 PMBL patients by means of a custom NGS panel for gene mutations and low-pass whole-genome sequencing (WGS) for copy number analysis (CNA) in a real-life setting. Appropriate cfDNA to perform the analyses was obtained in 18/20 cases. The sensitivity of cfDNA to detect the mutations present in paired FFPE samples was 69% (95% CI: 60-78%). The mutational landscape found in cfDNA samples was highly consistent with that of the tissue, with the most frequently mutated genes being

Identifiants

pubmed: 35885481
pii: diagnostics12071575
doi: 10.3390/diagnostics12071575
pmc: PMC9324191
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI16/00420 and PI19/00887 to ALG and EG, PI17/00313 to LC, PI19/0005 to BB and PI19/00034 to AS
Organisme : Centro de Investigación Biomédica en Red de Cáncer
ID : CB16/12/00334, CB16/12/00225 and CB16/12/00241
Organisme : European Union
ID : European Union's Horizon 2020 research and innovation programme and the Canadian Institutes of Health Research [grant number 825835 to EC
Organisme : European Hematology Association
ID : RG-202012-00245
Organisme : American Association For Cancer Research
ID : 2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, Grant Number 21-40-11-NADE
Organisme : Lady Tata Memorial Trust
ID : International Award for Research in Leukaemia 2021-2022, Grant Number LADY_TATA_21_3223
Organisme : Government of Catalonia
ID : 2018-BP-00055, ICREA AND CERCA PROGRAM

Références

Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Blood. 2018 Nov 29;132(22):2401-2405
pubmed: 30257882
Blood. 2019 Sep 5;134(10):802-813
pubmed: 31292115
Clin Cancer Res. 2021 Jan 15;27(2):513-521
pubmed: 33122345
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Sci Transl Med. 2016 Nov 9;8(364):364ra155
pubmed: 27831904
Br J Haematol. 2019 Apr;185(1):25-41
pubmed: 30740662
Diagnostics (Basel). 2020 Jun 30;10(7):
pubmed: 32629823
Leuk Lymphoma. 2022 Apr;63(4):834-844
pubmed: 35075971
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
J Clin Oncol. 2018 Oct 1;36(28):2845-2853
pubmed: 30125215
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
Br J Haematol. 2021 Jun;193(5):867-881
pubmed: 33550600
Blood. 2017 Apr 6;129(14):1947-1957
pubmed: 28096087
Am J Clin Pathol. 2021 Sep 8;156(4):497-512
pubmed: 34398178
Front Oncol. 2021 May 27;11:650122
pubmed: 34123798
Front Oncol. 2021 Mar 18;11:658234
pubmed: 33816315
Blood. 2016 Sep 8;128(10):1362-73
pubmed: 27335277
Blood. 2016 Apr 28;127(17):2122-30
pubmed: 26837699
Diagn Cytopathol. 2010 May;38(5):337-42
pubmed: 19890836
Blood. 2019 Dec 26;134(26):2369-2382
pubmed: 31697821
Cancer J. 2020 May/Jun;26(3):195-205
pubmed: 32496453
Blood Cancer J. 2018 Aug 1;8(8):74
pubmed: 30069017
Blood Adv. 2020 Jul 14;4(13):2886-2898
pubmed: 32589730
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943

Auteurs

Alfredo Rivas-Delgado (A)

Hematology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Faculty of Medicine and Health Sciences, Universitat de Barcelona, 08007 Barcelona, Spain.

Ferran Nadeu (F)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.

Marcio Andrade-Campos (M)

Hematology Department, Hospital del Mar-IMIM, 08003 Barcelona, Spain.
Grup de Recerca Clínica, Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM, 08003 Barcelona, Spain.

Cristina López (C)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.

Anna Enjuanes (A)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.

Pablo Mozas (P)

Hematology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.

Gerard Frigola (G)

Hematopathology Section, Pathology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.

Luis Colomo (L)

Pathology Department, Hospital del Mar-IMIM, 08003 Barcelona, Spain.
Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08002 Barcelona, Spain.

Blanca Sanchez-Gonzalez (B)

Hematology Department, Hospital del Mar-IMIM, 08003 Barcelona, Spain.
Grup de Recerca Clínica, Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM, 08003 Barcelona, Spain.

Neus Villamor (N)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
Hematopathology Section, Pathology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.

Sílvia Beà (S)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Faculty of Medicine and Health Sciences, Universitat de Barcelona, 08007 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
Hematopathology Section, Pathology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.

Elías Campo (E)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Faculty of Medicine and Health Sciences, Universitat de Barcelona, 08007 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
Hematopathology Section, Pathology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.

Antonio Salar (A)

Hematology Department, Hospital del Mar-IMIM, 08003 Barcelona, Spain.
Grup de Recerca Clínica, Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM, 08003 Barcelona, Spain.
Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08002 Barcelona, Spain.

Eva Giné (E)

Hematology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.

Armando López-Guillermo (A)

Hematology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Faculty of Medicine and Health Sciences, Universitat de Barcelona, 08007 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.

Beatriz Bellosillo (B)

Grup de Recerca Clínica, Aplicada en Neoplàsies Hematològiques-Hospital del Mar-IMIM, 08003 Barcelona, Spain.
Pathology Department, Hospital del Mar-IMIM, 08003 Barcelona, Spain.
Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08002 Barcelona, Spain.

Classifications MeSH